GemVax's Novel Peptide For Alzheimer’s Set To Advance After Positive Phase II
GemVax unveils positive topline results for South Korean Phase II study of novel peptide drug targeting patients with moderate to severe Alzheimer’s disease, raising hopes for the upcoming US trials.
You may also be interested in...
Biogen presented highly anticipated data in Alzheimer’s disease at CTAD for its Phase III EMERGE and ENGAGE studies, but one major question remains unanswered: will the FDA approve the drug?
Biogen and Eisai's surprise decision to advance Alzheimer’s antibody despite mixed clinical results could follow a similar path as pioneering neurodegenerative therapies Xenazine and Rilutek, or more recent Parkinson’s drug Nourianz – or could end with suspended development, like Kyndrisa.
After completing a major financing last year, expectations are rising at D&D Pharmatech as it progresses large-scale, Phase II global trials with its neuroinflammation pipeline for Parkinson’s and Alzheimer’s disease. Its CEO talks to Scrip about what's in store for the South Korean biotech.